Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease

20071,327 citationsJournal Articlebronze Open Access

Authors

Andrew J. Ullmann · Johannes Gutenberg University Mainz

Jeffrey H. Lipton · Princess Margaret Hospital

David H. Vesole · Medical College of Wisconsin

Pranatharthi Chandrasekar · Harper University Hospital

Amelia Langston · Emory University

Stefano Tarantolo · University of Nebraska Medical Center

Hildegard Greinix

Abstract

Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. It was superior in preventing invasive aspergillosis and reducing the rate of deaths related to fungal infections. (ClinicalTrials.gov number, NCT00034645 [ClinicalTrials.gov].).

Topics & Keywords

Antifungal resistance and susceptibility Fungal Infections and Studies Nail Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 4, pp. 335-347

DOI: 10.1056/nejmoa061098

Field-Weighted Citation Impact: 66.98